Jak skontaktować się z centrum
Centrum HCP
Zatrudniając około 14.100 XNUMX pracowników, UKE jest trzecim co do wielkości pracodawcą w Wolnym i Hanzeatyckim Mieście Hamburg.
Badania w UKE
Badania są ważnym warunkiem postępu w diagnostyce i terapii. Badania UKE kładą nacisk na neuronauki, badania układu krążenia, badania nad opieką, onkologię, a także infekcje i stany zapalne. Inne potencjalne obszary działalności UKE to badania z zakresu obrazowania molekularnego i biologii szkieletu.
Kontakt
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Zespół
Pr Martin Spitzer
Niemcy
Dr Johannes Birtel
Niemcy
Badania kliniczne
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
European Disease Registry on Retinopathy of Prematurity (ROP)
Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema Conditions
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma (DecodeVRL)
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER)